New research from Dr. Jung-Min Lee has identified a potential drug to treat ovarian cancers – NCI Center for Cancer Research
NCI Center for Cancer Research shared on LinkedIn:
“Milestones Monday: Ovarian cancer is the most lethal of all gynecological cancers.
Nearly a decade ago, the outlook for people diagnosed with ovarian cancer improved when drugs called PARP inhibitors were approved as a treatment for the disease. However, a new challenge has emerged for doctors who treat ovarian cancer: how to treat patients whose cancer has become resistant to PARP inhibitors, as most eventually do.
New research from Dr. Jung-Min Lee has identified a potential drug to treat ovarian cancers that have developed resistance to PARP inhibitors and a possible biomarker for those most likely to benefit from it.”
Source: NCI Center for Cancer Research/LinkedIn
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we“.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023